<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>A Brief Introduction to Multi-Stage Trials for Developing Dynamic Treatment Regimens</title>
    <meta charset="utf-8" />
    <meta name="author" content="Nicholas J. Seewald, Ph.D." />
    <script src="libs/header-attrs/header-attrs.js"></script>
    <link href="libs/tachyons/tachyons.min.css" rel="stylesheet" />
    <script src="libs/fabric/fabric.min.js"></script>
    <link href="libs/xaringanExtra-scribble/scribble.css" rel="stylesheet" />
    <script src="libs/xaringanExtra-scribble/scribble.js"></script>
    <script>document.addEventListener('DOMContentLoaded', function() { window.xeScribble = new Scribble({"pen_color":["#FF0000"],"pen_size":3,"eraser_size":30,"palette":[]}) })</script>
    <script src="libs/xaringanExtra_fit-screen/fit-screen.js"></script>
    <script src="libs/clipboard/clipboard.min.js"></script>
    <link href="libs/shareon/shareon.min.css" rel="stylesheet" />
    <script src="libs/shareon/shareon.min.js"></script>
    <link href="libs/xaringanExtra-shareagain/shareagain.css" rel="stylesheet" />
    <script src="libs/xaringanExtra-shareagain/shareagain.js"></script>
    <link rel="stylesheet" href="xaringan-themer.css" type="text/css" />
    <link rel="stylesheet" href="extras.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">
class: center, middle, inverse, title-slide

# A Brief Introduction to Multi-Stage Trials for Developing Dynamic Treatment Regimens
### Nicholas J. Seewald, Ph.D.
### 22 October 2021 

Working Group on Clinical Research, 
University of Rochester Medical Center

---

class: inverse, center, middle





# Follow along!

Slides are available at [urmc-smarts-2021.netlify.app](urmc-smarts-2021.netlify.app)

Materials are partially adapted from workshops given by the [d3lab](https://d3lab.isr.umich.edu) at the University of Michigan Institute for Social Research and from &lt;a name=cite-seewaldSequentialMultipleAssignment2021&gt;&lt;/a&gt;[Seewald, Hackworth, and Almirall (2021)](https://doi.org/10.1007/978-3-319-52677-5_280-1).

---
# What is a dynamic treatment regimen?

A **dynamic treatment regimen (DTR)** is

- an *intervention* design that 
- adapts the type, timing, intensity, or dose of treatment over time
- according to a patient's specific and changing needs.

--

In practice, a dynamic treatment regimen is a sequence of decision rules that can be used to guide how treatment can be adapted and readapted to an individual.

--
.center[
### Sounds a lot like clinical practice!
]

--
**MANY other names**: adaptive intervention, adaptive treatment strategy, individualized treatment rule, treatment algorithm, individualized intervention...

---
class: inverse, center, middle

# A dynamic treatment regimen is an *intervention design*, NOT an experimental design.

We'll talk about experiments soon!

---
# 5 components of a DTR

Dynamic treatment regimens consist of

1. Decision points
1. Tailoring variable(s)
1. Intervention options
1. Decision rule(s)
1. Proximal and distal outcomes

---
# Example DTR: Alcohol Use Disorder

- **Naltrexone** is known to diminish pleasurable effects of alcohol &lt;a name=cite-oslinTargetingTreatmentsAlcohol2006&gt;&lt;/a&gt;([Oslin, Berrettini, and O'Brien, 2006](https://doi.org/10/fgcfbk))

- Response to naltrexone is heterogeneous (adherence, biology, social support, etc.) &lt;a name=cite-nahum-shaniSMARTDataAnalysis2017&gt;&lt;/a&gt;([Nahum-Shani, Ertefaie, Lu, Lynch, McKay, Oslin, and Almirall, 2017](https://doi.org/10/ghpb9n))

- Heterogeneity necessitates a supportive intervention alongside naltrexone
  - **Medical management**: face-to-face clinical support + adherence monitoring
  - **Combined behavioral intervention**: targets patient's motivation for change, emphasizes social support &lt;a name=cite-longabaughOriginsIssuesOptions2005&gt;&lt;/a&gt;([Longabaugh, Zweben, Locastro, and Miller, 2005](https://doi.org/10/ghpb9f))

---
# Example DTR: Alcohol Use Disorder

![](images/PP_ClinTri_fig1.png)

--
1. Decision points
1. Tailoring variable(s)
1. Intervention options
1. Decision rule(s)
1. Proximal and distal outcomes

---
# Example DTR: Decision Points

A **decision point** is a time at which treatment might be adapted to the individual.

![:scale 90%](images/decision_points.png)
- **Decision point 1:** Treatment outset -- decide how to initiate treatment
- **Decision point 2:** Adjust treatment after 8 weeks

---
# Example DTR: Tailoring Variables

A **tailoring variable** is used to individualize treatment at each decision point. Can be static (age, baseline risk, etc.) or dynamic (adherence to treatment, disease severity, etc.)

![](images/tailoring_variable.png)

---
# Example DTR: Tailoring Variables

.center[![:scale 80%](images/tailoring_variable.png)]

Here, the tailoring variable is the **number of self-reported heavy drinking days following treatment initiation**.

- `\(\geq\)` 2 heavy drinking days `\(\rightarrow\)` _non-responder_
- `\(&lt;\)` 2 heavy drinking days `\(\rightarrow\)` _responder_

---
# Some Notes on Tailoring Variables

Note that the tailoring variable is _pre-specified_ and _well-defined_.

- Tailoring variables **are part of the intervention**!
  - Should be based on _practical_, _ethical_, or _scientific_ considerations.
  
--

.center[
### We'll come back to how to choose a tailoring variable.
]

---
# Example DTR: Intervention Options

- **Intervention options** at each decision point might be aspects of treatment: type, intensity, dose, delivery method, timing, etc.

- Here, intervention options are combinations of _naltrexone_, _medical management_, and _combined behavioral intervention_

.center[
  ![](images/intervention_options.png)
]

---
# Example DTR: Intervention Options

- In subsequent stages, could be _adaptation strategies_ like "augment", "intensify" or "stay the course".

.center[
  ![](images/intervention_options_strat.png)
]

---
# Example DTR: Decision Rules

.center[
  ![:scale 90%](images/decision_rule_init.png)
]

A **decision rule** recommends an _intervention option_ for individuals at each decision point, possibly based on prior information (i.e., a tailoring variable)

---
# Example DTR: Decision Rules

.center[
  ![:scale 90%](images/decision_rule.png)
]

A **decision rule** recommends an _intervention option_ for individuals at each decision point, possibly based on prior information (i.e., a tailoring variable)

---
# Example DTR: Proximal &amp; Distal Outcomes

A dynamic treatment regimen's design should be guided by both short-term (**proximal**) and long-term (**distal**) outcomes

- **Distal outcomes** are the long-term goals of the DTR
  - Long-term, example DTR should reduce _likelihood of alcohol use relapse_
  
- **Proximal outcomes** are the near-term goals of the DTR; perhaps a mechanism by which we can achieve the distal outcome.
  - Short-term, we want to lower risk of relapse by reducing the _proportion of drinking and heavy-drinking days over 8 weeks after adaptation_ &lt;a name=cite-leiSMARTDesignBuilding2012&gt;&lt;/a&gt;([Lei, Nahum-Shani, Lynch, Oslin, and Murphy, 2012](https://doi.org/10.1146/annurev-clinpsy-032511-143152))
  
---
# Scientific Questions about DTRs

Often unanswered questions about how to sequence and adapt interventions! Typically related to
  - relative effectiveness of different DTRs
  - relative effectiveness of different intervention options
  - how intervention options work with/against each other

--

###Common Questions
1. Which treatment option should the dynamic treatment regimen begin with?
1. How should we modify treatment for initial non-responders?
1. How should we modify treatment for initial responders?
1. How do we _define_ response/non-response?
1. How should we time decision points?

---
# Alcohol Use Disorder: Scientific Questions

- How do we define non-response to naltrexone in the context of a dynamic treatment regimen?
  - Unclear how many heavy drinking days indicate a need to augment treatment

- What treatments should be offered following the initial intervention (naltrexone + medical management)?
  - More intense support for non-responders?
  - Do responders need a supportive intervention alongside naltrexone?

--

## Let's now discuss an experimental design which can help answer these questions

---
class: inverse, middle, center

# Sequential, Multiple-Assignment Randomized Trials (SMARTs)

![](https://c.tenor.com/J2V8sWAs-igAAAAC/geek-cat-studious.gif)

---
# SMARTs

A **sequential, multiple-assignment randomized trial** is _one type_ of randomized trial design that can be used to answer questions at multiple stages of the development of a high-quality dynamic treatment regimen.

--

The key feature of a SMART is that some (or all) participants are randomized _more than once_.

---
# Example: The ExTENd Study (PI: D. Oslin)

.center[
  ![:scale 70%](images/ExTENd.png)
]

---
# 8 DTRs "embedded" in ExTENd

.center[
  ![:scale 70%](images/ExTENd_embedded_dtr1.png)
]

---
# 8 DTRs "embedded" in ExTENd

.center[
  ![:scale 70%](images/ExTENd_embedded_dtr2.png)
]
---
# 8 DTRs "embedded" in ExTENd

.center[
  ![:scale 70%](images/ExTENd_embedded_dtr3.png)
]

---
# 8 DTRs "embedded" in ExTENd

.center[
  ![:scale 70%](images/ExTENd_embedded_dtr4.png)
]

---
# 8 DTRs "embedded" in ExTENd

.center[
  ![:scale 70%](images/ExTENd_dtrs.gif)
]

---
# How do SMARTs inform DTR development?

Randomizations in a SMART correspond to open scientific questions about constructing a dynamic treatment regimen!

In ExTENd,

- First randomization seeks to answer a question about definition of non-response

- Second randomization in responders investigates whether lower-intensity medical management ("telehealth") is needed as maintenance therapy

- Second randomization in non-responders looks at the effect of naltrexone in the context of combined behavioral intervention + medical management

---
# Do I need a SMART?

SMARTs are designed to answer questions about the development of high-quality dynamic treatment regimes.

Consider a SMART if...

1. You want to develop a DTR
1. There are open questions preventing the construction of an effective DTR
1. There are open questions at _multiple decision points_ within a DTR

--

If any of these aren't true, you don't need a SMART!

---
# Do I need a SMART?
## What if we know what to do for responders?

.center[
  ![:scale 60%](images/ExTENd_hypothetical_noResp.png)
]

---
# Do I need a SMART?
## What if we know what to do for responders?

.center[
  ![:scale 70%](images/ExTENd_hypothetical_noResp_newTrial.png)
]


---
# Do I need a SMART?
## What if we know what to do initially?

.center[
  ![:scale 60%](images/ExTENd_hypothetical_init.png)
]

---
# Do I need a SMART?
## What if we know what to do initially?

.center[
  ![:scale 80%](images/ExTENd_hypothetical_init_newTrial.png)
]

---
# Design Considerations: Tailoring Variables

Tailoring variables are often used to **restrict randomization** (recommend different intervention options to different subgroups of participants)

Tailoring variables should be **well-justified**: remember, they're part of the DTRs!

You do **not** need to restrict randomization!

---
# Design Considerations: Tailoring Variables

If you restrict randomization, do so based on ethical, scientific, and/or practical considerations.

--

- **Ethical:** Treatment options should be appropriate for the subset of participants

--

- **Scientific:** Options should be based on already-established empirical evidence 

--

- **Practical:** You might save more intense or costly options for those who need it most (e.g.)

--

### Ultimately, _keep it simple_.

---
# Design Considerations: Aims

Focus on a few scientific aims about developing a high-quality DTR.


- **Primary aim:** Choose sample size based on this aim

- **Secondary aims:** Leverage rich data on treatment sequences to further inform a DTR

---
# Design Considerations: Primary Aims
## Compare initial intervention options

.center[
  ![:scale 60%](images/ExTENd_primary_stg1.png)
]

---
# Design Considerations: Primary Aims
## Compare initial intervention options
.pull-left[
.center[
![](images/ExTENd_primary_stg1.png)
]
]

.pull-right[
Hypothetical hypothesis might be:
&gt; A stringent definition of non-response in the context of a dynamic treatment regimen will lead to fewer heavy drinking days, on average, than a lenient definition of non-response.
]

---
# Design Considerations: Primary Aims
## Compare initial intervention options
.pull-left[
.center[
![](images/ExTENd_primary_stg1.png)
]
]

.pull-right[
- Analysis is just a two-group comparison of subgroups A-D vs. subgroups E-H
- Sample size requirements are the same as for a two-arm RCT.
]

---
# Design Considerations: Primary Aims
### Compare second-stage options among (non-)responders

.center[
  ![:scale 60%](images/ExTENd_primary_stg2r.png)
]

---
# Design Considerations: Primary Aims
### Compare second-stage options among (non-)responders

.pull-left[
.center[
  ![scale:60%](images/ExTENd_primary_stg2r.png)
]
]
.pull-right[
Hypothetical hypothesis:
&gt; Individuals who "respond" to naltrexone and medical management benefit more from naltrexone along with a telehealth intervention than naltrexone alone, on average, in terms of proportion of heavy drinking days after 8 weeks.

]

---
# Design Considerations: Primary Aimss
## Compare second-stage options among (non-)responders

.pull-left[
.center[
  ![scale:60%](images/ExTENd_primary_stg2r.png)
]
]
.pull-right[
- Analysis is a two-group comparison of subgroups A &amp; E vs. subgroups B &amp; F
- Sample size is as for a two-group comparison, upweighted by response rate.
]

---
# Design Considerations: Primary Aims
## Compare embedded dynamic treatment regimens

.center[
  ![:scale 60%](images/ExTENd_primary_dtr.png)
]

---
# Design Considerations: Primary Aims
## Compare embedded dynamic treatment regimens

.pull-left[
.center[
  ![](images/ExTENd_primary_dtr.png)
]
]

.pull-right[
  Hypothetical hypothesis:
  &gt; The red DTR will lead to fewer heavy drinking days after 8 weeks, on average, as compared to the blue DTR.
]

---
# Design Considerations: Primary Aims
## Compare embedded dynamic treatment regimens

.pull-left[
.center[
  ![](images/ExTENd_primary_dtr.png)
]
]

.pull-right[
- Analysis is *slightly* more complicated, but still 
- Sample size formulae available (see additional resources)
]


---
# Sample Size Resources
## for comparing dynamic treatment regimens

- **Continuous Outcomes:** &lt;a name=cite-oettingStatisticalMethodologySMART2011&gt;&lt;/a&gt;&lt;a name=cite-ogbagaberDesignSequentiallyRandomized2016&gt;&lt;/a&gt;[Oetting, Levy, Weiss, and Murphy (2011)](#bib-oettingStatisticalMethodologySMART2011); [Ogbagaber, Karp, and Wahed (2016)](https://doi.org/10.1002/sim.6747)
- **Binary Outcomes:** &lt;a name=cite-kidwellDesignAnalysisConsiderations2018&gt;&lt;/a&gt;[Kidwell, Seewald, Tran, Kasari, and Almirall (2018)](https://doi.org/10.1080/02664763.2017.1386773)
- **Survival Outcomes:** &lt;a name=cite-fengSampleSizeTwostage2009&gt;&lt;/a&gt;&lt;a name=cite-liSampleSizeFormulae2011&gt;&lt;/a&gt;[Feng and Wahed (2009)](https://doi.org/10.1002/sim.3593); [Li and Murphy (2011)](https://doi.org/10.1093/biomet/asr019)
- **Cluster-Randomized:** &lt;a name=cite-necampComparingClusterlevelDynamic2017&gt;&lt;/a&gt;[NeCamp, Kilbourne, and Almirall (2017)](https://doi.org/10.1177/0962280217708654)
- **Longitudinal:** &lt;a name=cite-seewaldSampleSizeConsiderations2020&gt;&lt;/a&gt;[Seewald, Kidwell, Nahum-Shani, Wu, McKay, and Almirall (2020)](https://doi.org/10/gf85ss)
- **Finding the best embedded DTR:** &lt;a name=cite-artmanPowerAnalysisSMART2018&gt;&lt;/a&gt;[Artman, Nahum-Shani, Wu, Mckay, and Ertefaie (2018)](https://doi.org/10/ggth75)

---
# Additional Reading

Materials from 3-day workshop on SMARTs and DTRs: &lt;https://d3lab.isr.umich.edu/workshop/getting-smart-about-adaptive-interventions-in-education-2019/&gt;

More in-depth, full book on DTRs:

Kosorok, M.R., and E.E.M. Moodie, eds. 2015. Adaptive Treatment Strategies in Practice: Planning Trials and Analyzing Data for Personalized Medicine. Philadelphia, PA: Society for Industrial and Applied Mathematics. https://doi.org/10.1137/1.9781611974188.

Overview of many different SMART in the field:

Lei, H., I. Nahum-Shani, K. Lynch, D. Oslin, and S.A. Murphy. “A ‘SMART’ Design for Building Individualized Treatment Sequences.” Annual Review of Clinical Psychology 8, no. 1 (2012): 21–48. https://doi.org/10.1146/annurev-clinpsy-032511-143152.

---
# Additional Reading

A nice introduction to SMARTs and DTRs in behavioral science:

Nahum-Shani, I., M. Qian, D. Almirall, W.E. Pelham, B. Gnagy, G.A. Fabiano, J.G. Waxmonsky, J. Yu, and S.A. Murphy. “Experimental Design and Primary Data Analysis Methods for Comparing Adaptive Interventions.” Psychological Methods 17, no. 4 (2012): 457–77. https://doi.org/10.1037/a0029372.

An introduction to "Q-learning" for building more "deeply tailored" DTRs:

Nahum-Shani, I., M. Qian, D. Almirall, W.E. Pelham, B. Gnagy, G.A. Fabiano, J.G. Waxmonsky, J. Yu, and S.A. Murphy. 2012. “Q-Learning: A Data Analysis Method for Constructing Adaptive Interventions.” Psychological Methods 17 (4): 478–94. https://doi.org/10.1037/a0029373.


---
# References

&lt;a name=bib-artmanPowerAnalysisSMART2018&gt;&lt;/a&gt;[Artman, W. J. et
al.](#cite-artmanPowerAnalysisSMART2018) (2018). "Power Analysis in a
SMART Design: Sample Size Estimation for Determining the Best Embedded
Dynamic Treatment Regime". In: _Biostatistics_. DOI:
[10/ggth75](https://doi.org/10%2Fggth75).

&lt;a name=bib-fengSampleSizeTwostage2009&gt;&lt;/a&gt;[Feng, W. et
al.](#cite-fengSampleSizeTwostage2009) (2009). "Sample Size for
Two-Stage Studies with Maintenance Therapy". In: _Statistics in
Medicine_ 28.15, pp. 2028-2041. ISSN: 0277-6715. DOI:
[10.1002/sim.3593](https://doi.org/10.1002%2Fsim.3593).

&lt;a name=bib-kidwellDesignAnalysisConsiderations2018&gt;&lt;/a&gt;[Kidwell, K. M.
et al.](#cite-kidwellDesignAnalysisConsiderations2018) (2018). "Design
and Analysis Considerations for Comparing Dynamic Treatment Regimens
with Binary Outcomes from Sequential Multiple Assignment Randomized
Trials". In: _Journal of Applied Statistics_ 45.9, pp. 1628-1651. ISSN:
0266-4763, 1360-0532. DOI:
[10.1080/02664763.2017.1386773](https://doi.org/10.1080%2F02664763.2017.1386773).

&lt;a name=bib-leiSMARTDesignBuilding2012&gt;&lt;/a&gt;[Lei, H. et
al.](#cite-leiSMARTDesignBuilding2012) (2012). "A "SMART" Design for
Building Individualized Treatment Sequences". In: _Annual Review of
Clinical Psychology_ 8.1, pp. 21-48. ISSN: 1548-5943, 1548-5951. DOI:
[10.1146/annurev-clinpsy-032511-143152](https://doi.org/10.1146%2Fannurev-clinpsy-032511-143152).

---
# References

&lt;a name=bib-liSampleSizeFormulae2011&gt;&lt;/a&gt;[Li, Z. et
al.](#cite-liSampleSizeFormulae2011) (2011). "Sample Size Formulae for
Two-Stage Randomized Trials with Survival Outcomes". In: _Biometrika_
98.3, pp. 503-518. ISSN: 00063444. DOI:
[10.1093/biomet/asr019](https://doi.org/10.1093%2Fbiomet%2Fasr019).

&lt;a name=bib-longabaughOriginsIssuesOptions2005&gt;&lt;/a&gt;[Longabaugh, R. et
al.](#cite-longabaughOriginsIssuesOptions2005) (2005). "Origins, Issues
and Options in the Development of the Combined Behavioral
Intervention." In: _J. Stud. Alcohol Suppl._, pp. 179-187. ISSN:
0363-468X. DOI: [10/ghpb9f](https://doi.org/10%2Fghpb9f).

&lt;a name=bib-nahum-shaniSMARTDataAnalysis2017&gt;&lt;/a&gt;[Nahum-Shani, I. et
al.](#cite-nahum-shaniSMARTDataAnalysis2017) (2017). "A SMART Data
Analysis Method for Constructing Adaptive Treatment Strategies for
Substance Use Disorders". In: _Addiction_ 112.5, pp. 901-909. ISSN:
1360-0443. DOI: [10/ghpb9n](https://doi.org/10%2Fghpb9n).

---
# References

&lt;a name=bib-necampComparingClusterlevelDynamic2017&gt;&lt;/a&gt;[NeCamp, T. et
al.](#cite-necampComparingClusterlevelDynamic2017) (2017). "Comparing
Cluster-Level Dynamic Treatment Regimens Using Sequential, Multiple
Assignment, Randomized Trials: Regression Estimation and Sample Size
Considerations". In: _Statistical Methods in Medical Research_ 26.4,
pp. 1572-1589. ISSN: 0962-2802, 1477-0334. DOI:
[10.1177/0962280217708654](https://doi.org/10.1177%2F0962280217708654).

&lt;a name=bib-oettingStatisticalMethodologySMART2011&gt;&lt;/a&gt;[Oetting, A. I.
et al.](#cite-oettingStatisticalMethodologySMART2011) (2011).
"Statistical Methodology for a SMART Design in the Development of
Adaptive Treatment Strategies". In: _Causality and Psychopathology:
Finding the Determinants of Disorders and Their Cures_. Ed. by P. E.
Shrout, K. M. Keyes and K. Ornstein. New York: Oxford University Press,
pp. 179-205. ISBN: 978-0-19-975464-9.

&lt;a name=bib-ogbagaberDesignSequentiallyRandomized2016&gt;&lt;/a&gt;[Ogbagaber,
S. B. et al.](#cite-ogbagaberDesignSequentiallyRandomized2016) (2016).
"Design of Sequentially Randomized Trials for Testing Adaptive
Treatment Strategies". In: _Statistics in Medicine_ 35.6, pp. 840-858.
DOI: [10.1002/sim.6747](https://doi.org/10.1002%2Fsim.6747).
---
# References

&lt;a name=bib-oslinTargetingTreatmentsAlcohol2006&gt;&lt;/a&gt;[Oslin, D. W. et
al.](#cite-oslinTargetingTreatmentsAlcohol2006) (2006). "Targeting
Treatments for Alcohol Dependence: The Pharmacogenetics of Naltrexone".
In: _Addiction Biology_ 11.3-4, pp. 397-403. ISSN: 1369-1600. DOI:
[10/fgcfbk](https://doi.org/10%2Ffgcfbk).

&lt;a name=bib-seewaldSequentialMultipleAssignment2021&gt;&lt;/a&gt;[Seewald, N. J.
et al.](#cite-seewaldSequentialMultipleAssignment2021) (2021).
"Sequential, Multiple Assignment, Randomized Trials (SMART)". In:
_Principles and Practice of Clinical Trials_. Ed. by S. Piantadosi and
C. L. Meinert. Cham: Springer International Publishing, pp. 1-19. ISBN:
978-3-319-52677-5. DOI:
[10.1007/978-3-319-52677-5_280-1](https://doi.org/10.1007%2F978-3-319-52677-5_280-1).

&lt;a name=bib-seewaldSampleSizeConsiderations2020&gt;&lt;/a&gt;[Seewald, N. J. et
al.](#cite-seewaldSampleSizeConsiderations2020) (2020). "Sample Size
Considerations for Comparing Dynamic Treatment Regimens in a Sequential
Multiple-Assignment Randomized Trial with a Continuous Longitudinal
Outcome". In: _Stat Methods Med Res_ 29.7, pp. 1891-1912. ISSN:
0962-2802. DOI: [10/gf85ss](https://doi.org/10%2Fgf85ss).

---
class: center, inverse, middle
# Reach out with questions (or ideas)! 

<svg aria-hidden="true" role="img" viewBox="0 0 512 512" style="height:1em;width:1em;vertical-align:-0.125em;margin-left:auto;margin-right:auto;font-size:inherit;fill:currentColor;overflow:visible;position:relative;"><path d="M464 64H48C21.49 64 0 85.49 0 112v288c0 26.51 21.49 48 48 48h416c26.51 0 48-21.49 48-48V112c0-26.51-21.49-48-48-48zm0 48v40.805c-22.422 18.259-58.168 46.651-134.587 106.49-16.841 13.247-50.201 45.072-73.413 44.701-23.208.375-56.579-31.459-73.413-44.701C106.18 199.465 70.425 171.067 48 152.805V112h416zM48 400V214.398c22.914 18.251 55.409 43.862 104.938 82.646 21.857 17.205 60.134 55.186 103.062 54.955 42.717.231 80.509-37.199 103.053-54.947 49.528-38.783 82.032-64.401 104.947-82.653V400H48z"/></svg> [nseewal1@jhu.edu](mailto:nseewal1@jhu.edu)

<svg aria-hidden="true" role="img" viewBox="0 0 512 512" style="height:1em;width:1em;vertical-align:-0.125em;margin-left:auto;margin-right:auto;font-size:inherit;fill:currentColor;overflow:visible;position:relative;"><path d="M459.37 151.716c.325 4.548.325 9.097.325 13.645 0 138.72-105.583 298.558-298.558 298.558-59.452 0-114.68-17.219-161.137-47.106 8.447.974 16.568 1.299 25.34 1.299 49.055 0 94.213-16.568 130.274-44.832-46.132-.975-84.792-31.188-98.112-72.772 6.498.974 12.995 1.624 19.818 1.624 9.421 0 18.843-1.3 27.614-3.573-48.081-9.747-84.143-51.98-84.143-102.985v-1.299c13.969 7.797 30.214 12.67 47.431 13.319-28.264-18.843-46.781-51.005-46.781-87.391 0-19.492 5.197-37.36 14.294-52.954 51.655 63.675 129.3 105.258 216.365 109.807-1.624-7.797-2.599-15.918-2.599-24.04 0-57.828 46.782-104.934 104.934-104.934 30.213 0 57.502 12.67 76.67 33.137 23.715-4.548 46.456-13.32 66.599-25.34-7.798 24.366-24.366 44.833-46.132 57.827 21.117-2.273 41.584-8.122 60.426-16.243-14.292 20.791-32.161 39.308-52.628 54.253z"/></svg> [@nickseewald](https://twitter.com/nickseewald)

<svg aria-hidden="true" role="img" viewBox="0 0 512 512" style="height:1em;width:1em;vertical-align:-0.125em;margin-left:auto;margin-right:auto;font-size:inherit;fill:currentColor;overflow:visible;position:relative;"><path d="M326.612 185.391c59.747 59.809 58.927 155.698.36 214.59-.11.12-.24.25-.36.37l-67.2 67.2c-59.27 59.27-155.699 59.262-214.96 0-59.27-59.26-59.27-155.7 0-214.96l37.106-37.106c9.84-9.84 26.786-3.3 27.294 10.606.648 17.722 3.826 35.527 9.69 52.721 1.986 5.822.567 12.262-3.783 16.612l-13.087 13.087c-28.026 28.026-28.905 73.66-1.155 101.96 28.024 28.579 74.086 28.749 102.325.51l67.2-67.19c28.191-28.191 28.073-73.757 0-101.83-3.701-3.694-7.429-6.564-10.341-8.569a16.037 16.037 0 0 1-6.947-12.606c-.396-10.567 3.348-21.456 11.698-29.806l21.054-21.055c5.521-5.521 14.182-6.199 20.584-1.731a152.482 152.482 0 0 1 20.522 17.197zM467.547 44.449c-59.261-59.262-155.69-59.27-214.96 0l-67.2 67.2c-.12.12-.25.25-.36.37-58.566 58.892-59.387 154.781.36 214.59a152.454 152.454 0 0 0 20.521 17.196c6.402 4.468 15.064 3.789 20.584-1.731l21.054-21.055c8.35-8.35 12.094-19.239 11.698-29.806a16.037 16.037 0 0 0-6.947-12.606c-2.912-2.005-6.64-4.875-10.341-8.569-28.073-28.073-28.191-73.639 0-101.83l67.2-67.19c28.239-28.239 74.3-28.069 102.325.51 27.75 28.3 26.872 73.934-1.155 101.96l-13.087 13.087c-4.35 4.35-5.769 10.79-3.783 16.612 5.864 17.194 9.042 34.999 9.69 52.721.509 13.906 17.454 20.446 27.294 10.606l37.106-37.106c59.271-59.259 59.271-155.699.001-214.959z"/></svg> [nickseewald.com](https://www.nickseewald.com)
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script src="macros.js"></script>
<script>var slideshow = remark.create({
"highlightStyle": "github",
"highlightLines": true,
"countIncrementalSlides": false,
"slideNumberFormat": "%current%",
"ratio": "16:9"
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
(function() {
  "use strict"
  // Replace <script> tags in slides area to make them executable
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    var scriptAttrs = scripts[i].attributes;
    for (var j = 0; j < scriptAttrs.length; j++) {
      s.setAttribute(scriptAttrs[j].name, scriptAttrs[j].value);
    }
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();
// adds .remark-code-has-line-highlighted class to <pre> parent elements
// of code chunks containing highlighted lines with class .remark-code-line-highlighted
(function(d) {
  const hlines = d.querySelectorAll('.remark-code-line-highlighted');
  const preParents = [];
  const findPreParent = function(line, p = 0) {
    if (p > 1) return null; // traverse up no further than grandparent
    const el = line.parentElement;
    return el.tagName === "PRE" ? el : findPreParent(el, ++p);
  };

  for (let line of hlines) {
    let pre = findPreParent(line);
    if (pre && !preParents.includes(pre)) preParents.push(pre);
  }
  preParents.forEach(p => p.classList.add("remark-code-has-line-highlighted"));
})(document);</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
